How do I choose between different biologics CDMO providers for upstream capacity, downstream recovery, and sterile fill-finish?

Choosing a biologics CDMO is mostly about matching what you need to outsource with where the technical and operational risk sits in your program.

A practical way to compare providers is to evaluate them separately for:

1. Upstream capacity
2. Downstream recovery/purification
3. Sterile fill-finish

Then score each provider on a common set of criteria: technical fit, scale, quality/compliance, capacity, speed, and commercial terms.

1) Start with your own program requirements

Before comparing vendors, define:

• Molecule type: mAb, bispecific, Fc-fusion, enzyme, viral vector, etc.
• Expression system: CHO, HEK, microbial, etc.
• Development stage: process dev, tox, Phase 1/2/3, commercial
• Batch size and annual volume needs
• Required titer, yields, purity, and product quality attributes
• Formulation and storage needs
• Sterility assurance expectations
• Geography/regulatory markets: FDA, EMA, MHRA, PMDA, etc.
• Timeline and risk tolerance
• Whether you need one integrated CDMO or best-of-breed vendors

This determines whether you need a provider that is strong in one unit operation or one that can handle the whole end-to-end chain.

---

2) How to evaluate upstream capacity

Upstream is about whether the CDMO can reliably produce enough high-quality biomass or harvestable product.

Key evaluation criteria

• Platform fit
  • Do they have an established process platform for your molecule type?
  • How much process customization is required?
• Bioreactor scale and flexibility
  • Available scales: bench, pilot, 2kL, 5kL, 10kL+, etc.
  • Single-use vs stainless steel options
  • Ability to run multiple campaigns in parallel
• Real capacity, not just installed capacity
  • Ask about actual utilization and scheduled backlog
  • How much capacity is reserved for existing clients?
• Process performance
  • Typical titers and productivity ranges
  • Batch success rates
  • Contamination history
  • Hold times and in-process controls
• Tech transfer capability
  • Experience transferring from your process or platform
  • Documentation quality and speed of PPQ readiness
• Supply chain resilience
  • Media, resins, single-use components, filters, and buffer supply
  • Dual sourcing and inventory strategy
• MSAT and analytics support
  • Strength of process sciences, automation, and data systems

Questions to ask

• What is your current upstream occupancy rate?
• How many campaigns can you run simultaneously for my molecule class?
• What are your typical cycle times from inoculation to harvest?
• What is your average batch failure rate over the last 2–3 years?
• What titer range do you support at commercial scale?
• How quickly can you scale from development to GMP?

Red flags

• Installed capacity that is heavily booked
• No clear platform for your modality
• Overpromising on scale without data
• Weak raw material sourcing or frequent equipment constraints

---

3) How to evaluate downstream recovery

Downstream often determines purity, yield, cost of goods, and scalability.

Key evaluation criteria

• Experience with your product class
  • Different purification challenges for mAbs, fragments, viral proteins, enzymes, etc.
• Purification train design
  • Protein A, ion exchange, HIC, mixed-mode, filtration, viral clearance, polishing
• Yield and purity performance
  • Step yields
  • Aggregate and impurity clearance
  • Host cell protein and DNA removal
• Scalability
  • Can small-scale methods translate to commercial equipment?
  • Resin lifetime and lifetime validation
• Virus clearance and safety
  • Proven viral inactivation and filtration strategy
  • Validation package quality
• Process robustness
  • Sensitivity to feed variation, pH, conductivity, temperature
• Analytical capability
  • Method development, characterization, release testing, comparability support
• Consumables and resin strategy
  • Resin availability, reuse strategy, and supply constraints

Questions to ask

• What are your typical overall recovery yields for similar molecules?
• How many downstream platforms do you have already validated?
• What is your approach to viral clearance validation?
• How do you handle resin lifetime studies and cleaning validation?
• What is your track record for HCP/DNA clearance at high loads?

Red flags

• Generic downstream claims without product-class specifics
• No demonstrated validation experience
• Limited analytical support
• Unclear resin sourcing or proprietary bottlenecks

---

4) How to evaluate sterile fill-finish

Fill-finish is about sterility, integrity, and reliable delivery of drug product.

Key evaluation criteria

• Aseptic capability
  • Is the site true aseptic fill-finish or reliant on terminal sterilization?
  • Barrier technology: isolators vs RABS vs traditional cleanrooms
• Container closure formats
  • Vials, syringes, cartridges, BFS, etc.
  • Compatibility with your formulation and market needs
• Line flexibility and speed
  • Small-batch clinical fill and large-scale commercial fill
  • Changeover efficiency
• Sterility assurance and contamination control
  • Environmental monitoring performance
  • Media fill history
  • Investigations and deviation handling
• Formulation and drug product services
  • Lyophilization capability
  • Cold chain, frozen storage, handling of sensitive proteins
• Visual inspection and packaging
  • Inspection capabilities
  • Serialization and labeling support
• Regulatory inspection history
  • FDA/EMA inspection outcomes
  • Warning letters, consent decrees, or recurring observations
• Capacity and scheduling
  • Line availability is often a bottleneck
  • Ask how far out slots are booked

Questions to ask

• What aseptic technology do you use, and why?
• How many media fills have you completed successfully?
• What is your deviation and sterility failure history?
• Can you support my dosage form and container closure system?
• How far out is commercial fill capacity booked?

Red flags

• Weak contamination control history
• Limited experience with your dosage form
• No lyophilization if you need it
• Long lead times for line slots
• Poor regulatory track record

---

5) Decide whether to use one CDMO or multiple providers

Use one integrated CDMO if:

• You want simpler tech transfer and accountability
• Your program is early stage or resource-constrained
• The provider has strong capabilities across all three areas
• Speed and coordination matter more than best-in-class specialization

Use multiple providers if:

• One vendor is strong in upstream, another in fill-finish
• Your product needs specialized downstream expertise
• You want to reduce single-point-of-failure risk
• You need regional manufacturing redundancy
• Capacity is tight in one segment

Tradeoff

• Integrated CDMO: simpler, fewer handoffs, but may be less specialized
• Best-of-breed network: more flexibility and expertise, but more complex management and tech transfer risk

---

6) Build a scorecard

A simple weighted scorecard helps compare providers objectively.

Example criteria and weights

• Technical fit: 25%
• Quality/compliance: 20%
• Real capacity and scalability: 20%
• Timeline and responsiveness: 15%
• Commercial terms: 10%
• Geographic/regulatory fit: 10%

Then score each provider for:

• Upstream
• Downstream
• Fill-finish

You may find one provider is:

• Excellent in upstream
• Average in downstream
• Weak in fill-finish

That often argues for splitting the program rather than forcing a single vendor.

---

7) Due diligence checklist

Request:

• Facility description and equipment list
• Capacity calendar and current utilization
• Recent audit reports or inspection summary
• Quality metrics: deviations, OOS, contamination, right-first-time
• Regulatory history
• Process platform data relevant to your molecule class
• Project plan and tech transfer timeline
• Named team bios
• Business continuity and supply chain plans
• Change control and comparability procedures
• Sample MSA/SOW and pricing model

---

8) Practical decision rule

If you want a simple rule of thumb:

• Choose the CDMO with the strongest proven track record in your highest-risk step
• Make sure the other steps are at least “good enough” and capacity-secure
• Avoid paying for “full service” if one part is clearly weak
• Don’t choose based on installed capacity alone; choose based on available, qualified capacity

---

If you want, I can also give you:

1. a vendor comparison scorecard template,
2. a list of due-diligence questions by function, or
3. a decision matrix for single-vendor vs split-vendor outsourcing.